RT Journal Article
SR Electronic
T1 Serious underlying medical conditions and COVID-19 vaccine hesitancy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.06.22273080
DO 10.1101/2022.04.06.22273080
A1 Day, Daphne
A1 Grech, Lisa
A1 Nguyen, Mike
A1 Bain, Nathan
A1 Kwok, Alastair
A1 Harris, Sam
A1 Chau, Hieu
A1 Chan, Bryan
A1 Blennerhassett, Richard
A1 Nott, Louise
A1 Hamad, Nada
A1 Tognela, Annette
A1 Hoffman, David
A1 McCartney, Amelia
A1 Webber, Kate
A1 Wong, Jennifer
A1 Underhill, Craig
A1 Sillars, Brett
A1 Winkel, Antony
A1 Savage, Mark
A1 Loe, Bao Sheng
A1 Freeman, Daniel
A1 Segelov, Eva
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/04/06/2022.04.06.22273080.abstract
AB Objective To examine vaccine uptake, hesitancy and explanatory factors amongst people with serious and/or chronic health conditions, including the impact of underlying disease on attitudes to vaccination.Design Cross-sectional survey.Setting Ten Australian health services.Participants 4683 patients (3560 cancer, 842 diabetes and 281 multiple sclerosis) receiving care at the health services participated in the 42-item survey, between June 30 to October 5, 2021.Main outcome measures Sociodemographic and disease-related characteristics, COVID-19 vaccine uptake, and the scores of three validated scales which measured vaccine hesitancy and vaccine-related beliefs generally and specific to the participants’ disease, including the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale and the Disease Influenced Vaccine Acceptance Scale. Multivariable logistic regression was used to determine the associations between scale scores and vaccine uptake.Results Of all participants, 81.5% reported having at least one COVID-19 vaccine. Unvaccinated status was associated with younger age, female sex, lower education and income, English as a second language, and residence in regional areas (all p<0.05). Unvaccinated participants were more likely to report greater vaccine hesitancy and more negative perceptions toward vaccines (all p<0.05). Disease-related vaccine concerns were associated with unvaccinated status and hesitancy, including greater complacency about COVID-19 infection, and concerns relating to vaccine efficacy and impact on their disease and/or treatment (all p<0.05).Conclusions Disease-specific concerns impact COVID-19 vaccine-related behaviours and beliefs in people with serious and/or chronic health conditions. This highlights the need to develop targeted strategies and education about COVID-19 vaccination to support medically vulnerable populations and health professionals.Trial registration ACTRN12621001467820Competing Interest StatementLG and Monash University were awarded grant funding from Merck Pharmaceuticals, outside of the submitted work. DD received research support (clinical trials for institution) from: Beigene, Bristol-Myers Squibb, EpimAb, Harbour BioMed, Maxinovel, MSD, Olema Pharmaceuticals, Pfizer, PhamAbcine, and RocheFunding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Ethics Committee of Monash Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.